On Nov. 18, 2016, the U.S. Food and Drug Administration (FDA) approved extending the age range for use of FluLaval Quadrivalent, manuafactured by ID Biomedical, to include children 6 to 35 months of age.

Indications included active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.